The Simultaneous Onset of Pancreatitis and Colitis as Immune-related Adverse Events in a Patient Receiving Nivolumab Treatment for Renal Cell Carcinoma.

Internal medicine (Tokyo, Japan) 2022 May 15

filter terms:

Immune checkpoint inhibitors (ICIs), which have anti-tumor effects, are currently approved for treatment of several kinds of advanced malignancies. However, with their increasing use, a variety of immune-related adverse events (irAEs) in administered patients have been reported. We herein report a rare case of the simultaneous onset of acute pancreatitis and colitis as irAEs during nivolumab treatment given to a patient with renal cell carcinoma, who then shown marked improvement with corticosteroid therapy.

Citation

Tomotaka Yazaki, Ichiro Moriyama, Hiroshi Tobita, Hiroki Sonoyama, Eiko Okimoto, Akihiko Oka, Yoshiyuki Mishima, Naoki Oshima, Kotaro Shibagaki, Kousaku Kawashima, Norihisa Ishimura, Taichi Nagami, Riruke Maruyama, Hiroaki Shiina, Shunji Ishihara. The Simultaneous Onset of Pancreatitis and Colitis as Immune-related Adverse Events in a Patient Receiving Nivolumab Treatment for Renal Cell Carcinoma. Internal medicine (Tokyo, Japan). 2022 May 15;61(10):1485-1490